Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Stock Traders Daily
Provider: New Constructs, LLC
Provider: MacroRisk Analytics/EconomicInvestor

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Repligen Corp Issues FY 2013 Guidance

Thursday, 7 Mar 2013 07:30am EST 

Repligen Corp announced that for fiscal 2013, it expects total revenue to be $63-$65 million, including the receipt of royalties from Bristol-Myers Squibb on its U.S. sales of Orencia which the Company will no longer receive after December 31, 2013. Net income for fiscal 2013 is expected to be $18-$20 million. 

Company Quote

0.4 +2.02%
26 Dec 2014